SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3507REGENERON APPLAUDS SUPREME COURT’S UNANIMOUS OPINION STRIKING DOWN AMGEN’S PCSK9Biotechwantabe-5/18/2023
3506Yes, any we’ll have to wait 2 quarters to find out it 8mg can steam the tide.Biotechwantabe15/4/2023
3505Looks like the market was correct to worry about Vabysmo, investors.comA.J. Mullen-5/4/2023
3504Lilly’s Alzheimer Results More evidence that clearing the plaque works. Helps Biotechwantabe-5/3/2023
3503Q1 Roche Zabysmo doing well +432. Does it impact Eylea growth? Probably what’s sA.J. Mullen-4/27/2023
3502biopharmadive.com Option articleBiotechwantabe-4/27/2023
3501Vabismo is already selling at a $2B annualized rate. Roche considers Vabismo to DewDiligence_on_SI-4/27/2023
3500Q1 Dupi +40%. Wow Q1 cov2 Roche shipment to Japan +568m. Not expected. Q1 RocheBiotechwantabe-4/27/2023
3499It’s safe and showed reduction of Ab in humans. FDA partial hold seem temporary Biotechwantabe-4/27/2023
3498Thoughts on ALN-APP? investor.regeneron.comFelix B-4/26/2023
3497A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Biotechwantabe-3/29/2023
3496My buddy and his son were very happy with dupixent and had clear skin. Amusinglypheilman_-3/20/2023
3495Regeneron Pharmaceuticals, Inc. Sat, March 18, 2023 at 7:00 AM PDT More than twA.J. Mullen-3/19/2023
34942023 guesstimate Dupi 8.68b +35% +3b Eylea 9.65b (hard to project +/-) 0 LibtaBiotechwantabe-3/1/2023
3493REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESUBiotechwantabe-2/3/2023
3492Thanks for all info. 1H 2023 will be interesting, think.Miljenko Zuanic-1/16/2023
3491I was thinking it was an insurance fund that was out of money, but as you say, iA.J. Mullen-1/13/2023
3490It is all about co-pay assistance. Someone need to pay difference between what iMiljenko Zuanic-1/13/2023
3489You clearly follow closer than I do. The CEO said it was because of a single fuA.J. Mullen-1/11/2023
3488Co-pay story for end-of-year (4Q relative weak sale) is "standard", foMiljenko Zuanic-1/11/2023
3487Did they cover story on Eylea 4Q sale decline blaming Avastin and copay? ThatA.J. Mullen-1/10/2023
3486Did they cover story on Eylea 4Q sale decline blaming Avastin and copay? Every yMiljenko Zuanic11/10/2023
3485Worth listening to conference call. Nice dip to buy some more. Presentation at Biotechwantabe11/9/2023
3484He has a number of good points and I appreciate his enthusiasm although I can alFelix B-12/12/2022
3483George had a very good point. IMO, If it wasn’t for the American drug pricing,Biotechwantabe-12/12/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News